ALTAO — Aton SA Share News
0.000.00%
Last trade - 00:00- €9.44m
- €14.28m
- €0.66m
Brief: Hybrigenics announces results from Phase II study on inecalcitol
Brief: Hybrigenics H1 net loss widens to 2.9 million euros
Brief: Hybrigenics receives a milestone payment of 1.5 million euros
Brief: Hybrigenics recruits first patient in the clinical study of Inecalcitol
Brief: Hybrigenics FY net loss widens to 4.3 mln euros
French and Benelux stocks-Factors to watch on Jan 12
Brief: Hybrigenics gets FDA approval for inecalcitol phase II study
Brief: Hybrigenics gets authorization for clinical Phase II study of inecalcitol
Brief: Hybrigenics to present new in vitro data on inecalcitol in chronic myeloid leukemia
Brief: Hybrigenics H1 net loss widens to 2.3 million euros
Brief: Hybrigenics says Inecalcitol gets orphan drug designation
Brief: Hybrigenics H1 revenue stable at 1.9 million euros
Brief: Hybrigenics appoints Alain Munoz chairman
Brief: Hybrigenics FY net loss widens to 2.9 million euros
Brief: Hybrigenics raises total of 9 million euros
Brief: Hybrigenics launches 7 million euro capital increase
Brief: Hybrigenics FY operating revenue rises to 6.0 mln euros
Brief: Hybrigenics extends its partnership with Servier
Brief: Hybrigenics launches phase II study of Inecalcitol